Buparlisib (BKM120, NVP-BKM120)

Catalog No.S2247

Buparlisib (BKM120, NVP-BKM120) Chemical Structure

Molecular Weight(MW): 410.39

Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Phase 2.

Size Price Stock Quantity  
In DMSO USD 272 In stock
USD 170 In stock
USD 320 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 51 Publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Phase 2.
Targets
p110α [1]
(Cell-free assay)
p110δ [1]
(Cell-free assay)
p110β [1]
(Cell-free assay)
p110γ [1]
(Cell-free assay)
Vps34 [1]
(Cell-free assay)
52 nM 116 nM 166 nM 262 nM 2.4 μM
In vitro

BKM120 is not sensitive to Class III and Class IV PI3K's or PI4K. NVP-BKM120 shows great antiproliferation activity to PI3K deregulated cell lines including A2780, U87MG, MCF7 and DU145 with GI50 of 0.1-0.7 nM. [1] BKM120 induces multiple myeloma cells (ARP1, ARK, MM.1S, MM1.R and U266) apoptosis, which results in increased G1-phase cells and decreased S-phase cells. BKM120 induced CD138+ primary MM cell apoptosis and has significant lower cytotoxicity toward CD138− stromal cells. BKM120 exposure could cause upregulation of BimS and downregulation of XIAP. [2] BKM120 demonstrates antiproliferative activity in human gastric cancer cell lines by decreasing mTOR downstream signaling. BKM120 could increase either p-ERK or p-STAT3 in KRAS mutant gastric cancer cells. Combination with STAT3 blockade, BKM120 shows a synergism in cells harboring mutated KRAS by inducing apoptosis, but not in KRAS wild-type cells. [3] A recent study shows that BKM120 shows differential forms of cell death on the basis of p53 status of the cells with p53 wild-type cells undergoing apoptotic cell death and p53 mutant/deleted cells having a mitotic catastrophe cell death. BKM120 mediates mitotic catastrophe mainly through Aurora B kinase. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 M1flN2N6fG:2b4jpZ{BCe3OjeR?= MYO3NkBp MlT1SG1UVw>? M3T6[mN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh\XiycnXzd4lv\yCSSUPLZYxxcGFiRUW0OWshdXW2YX70JJdqfGhiR1m1NEBw\iByLkCwNFE2QCEQvF2= NVTGb4pEOjR7MECyOlY>
DU145 MoLtR5l1d3SxeHnjJGF{e2G7 M3e0RVczKGh? MYLEUXNQ MXXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDEWVE1PSClZXzsd{BmgHC{ZYPzbY5oKEyNQkGgcZV1[W62IIfpeIghT0l3MDDv[kAxNjByMESzOUDPxE1? NVP2[WRCOjR7MECyOlY>
A2780 NHziRWhEgXSxdH;4bYMhSXO|YYm= NXLKU5lZPzJiaB?= MoDBSG1UVw>? MUTDfZRwfG:6aXPpeJkh[WejaX7zeEBRXEWQLXTl[olkcWWwdDDoeY1idiCDMke4NEBk\WyuczD3bZRpKEeLNUCgc4YhOC5yMEC2N|Uh|ryP MYKyOFkxODJ4Nh?=
U87MG MWfDfZRwfG:6aXOgRZN{[Xl? MoHhO|IhcA>? MYrEUXNQ NEPm[|JEgXSxdH;4bYNqfHliYXfhbY5{fCCSVFXOMYRm\mmlaXXueEBpfW2jbjDVPFdOTyClZXzsd{B4cXSqIFfJOVAhd2ZiMD6wNFA3QThizszN MUGyOFkxODJ4Nh?=
A2780 NVy5SY5DTnWwY4Tpc44hSXO|YYm= MVGxJIg> MVvEUXNQ Mn;6TY5pcWKrdHnvckBw\iCSSUPLMY1m\GmjdHXkJGFMXCCVZYK0O|MheGixc4Doc5J6dGG2aX;uJJdqfGhiRVO1NEBw\iByLkC1OUDPxE1? NEXWNnIzPDlyMEK2Oi=>
DU145 NXXm[JZDTnWwY4Tpc44hSXO|YYm= M4fzTFEhcA>? MV7EUXNQ NUX5XIFSUW6qaXLpeIlwdiCxZjDQTVNMNW2nZHnheIVlKEGNVDDT[ZI1PzNicHjvd5Bpd3K7bHH0bY9vKGmwIHj1cYFvKESXMUS1JINmdGy|IHjhdoJwemmwZzDMT2IyKG23dHH0bY9vKHerdHigSWM2OCCxZjCwMlA4OyEQvF2= NX7TeWc6OjR7MECyOlY>
A2780 M1TZ[2Z2dmO2aX;uJGF{e2G7 MnraNUBp NWXsOoZwTE2VTx?= NWTV[XZ7UW6qaXLpeIlwdiCxZjDQTVNMNW2nZHnheIVlKEGNVDDT[ZI1PzNicHjvd5Bpd3K7bHH0bY9vKGmwIGDUSW4u\GWoaXPp[Y51KGi3bXHuJGEzPzhyIHPlcIx{KHerdHigSWM2OCCxZjCwMlA4PCEQvF2= M1\oU|I1QTByMk[2
MCF7 Mn[4SpVv[3Srb36gRZN{[Xl? MoL3NUBp NGLDSWdFVVOR NXXNfG1xUW6qaXLpeIlwdiCxZjDQTVNM[WyyaHGgSVU1PUtibYX0ZY51NW2nZHnheIVlKEGNVDDT[ZI1PzNicHjvd5Bpd3K7bHH0bY9vKHerdHigSWM2OCCxZjCwMlEh|ryP MYiyOFkxODJ4Nh?=
U87MG NXTJWHBnTnWwY4Tpc44hSXO|YYm= MXixJIg> MnHISG1UVw>? MV3Jcohq[mm2aX;uJI9nKFCLM1utcYVlcWG2ZXSgRWtVKFOnckS3N{BxcG:|cHjvdplt[XSrb36gbY4hWFSHTj3k[YZq[2mnboSgbJVu[W5iVUi3UWch[2WubIOge4l1cCCHQ{WwJI9nKDBwMUOg{txO MXOyOFkxODJ4Nh?=
A2780 MorYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXe3NkBp NHf1OlZFVVOR NFXTR2NGSzVyPUCuOVIh|ryP NHvuRYgzPDlyMEK2Oi=>
SKMES-1 NWToPZlxS3m2b4TvfIlkKEG|c3H5 MmKzNUDPxE1? MoryO|IhcA>? NXTQcWhkUW6mdXPld{Bk\WyuIHTlZZRp NIL0N|AzPjBzM{OxPC=>
H596 MmrISpVv[3Srb36gRZN{[Xl? MkjTNUDPxE1? M{D3cmlueGGrcoOgZ4VtdCCvaXfyZZRqd25? MUeyOlAyOzNzOB?=
HCC2450 MYLGeY5kfGmxbjDBd5NigQ>? MknaNUDPxE1? MmXtTY1x[Wm{czDj[YxtKGmwdnHzbY9v NV7OXnkzOjZyMUOzNVg>
A549 NWOwUG5{TnWwY4Tpc44hSXO|YYm= MYS1NFAhdk1? MXG0PEBp NHzMSWRFVVOR NYjHOo5MUW6qaXLpeJMhSWu2IHHjeIl3[XSrb36= NYjWepFtOjV7M{eyPVk>
A549 NHmxeWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XMSVEh|ryP M1rMclczKGh? NYPac4N1TE2VTx?= MWXJcohq[mm2czDj[YxtKGe{b4f0bC=> NVLMTWx3OjV7M{eyPVk>
H522 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3yWW92OSEQvF2= M336W|czKGh? MkDDSG1UVw>? MUTJcohq[mm2czDj[YxtKGe{b4f0bC=> NHW5bXozPTl|N{K5PS=>
LNCaP MlnuSpVv[3Srb36gRZN{[Xl? NWPnVlh5OSEQvF2= MkHLV5VxeHKnc4Pld{BxNUGNVDDs[ZZmdHN? MkTGNlU{PjB5OUm=
LNCaP95 Mn\xSpVv[3Srb36gRZN{[Xl? NES0UIUyKM7:TR?= NYrWOFg{W3WycILld5NmeyCyLVHLWEBt\X[nbIO= MlP1NlU{PjB5OUm=
HCT-15 M1HOSWFxd3Sxc3nzJGF{e2G7 NVXMVZdiOTBizszN NGHieIE1QCCq Mon5SG1UVw>? NGjrcFBKdmS3Y3XzJIFxd3C2b4Ppd{BqdiCKQ2StNVUh[2WubIOgbIFz[m:3cnnu[{BRUUt|Q1GgbI91e3CxdDDteZRifGmxbh?= M{D4OVI2OTV{MkS1
HCT-116 M2r4V2Fxd3Sxc3nzJGF{e2G7 NID2eXkyOCEQvF2= MVe0PEBp MlWwSG1UVw>? MofFTY5lfWOnczDhdI9xfG:|aYOgbY4hUEOWLUGxOkBk\WyuczDoZZJjd3W{aX7nJHBKUzOFQTDoc5R{eG:2IH31eIF1cW:w NVzLNFNTOjVzNUKyOFU>
NCI-H460 MWnBdI91d3OrczDBd5NigQ>? MlrKNVAh|ryP NW\E[ZVKPDhiaB?= NGOz[WdFVVOR MkHuTY5lfWOnczDhdI9xfG:|aYOgbY4hVkOLLVi0OlAh[2WubIOgbIFz[m:3cnnu[{BRUUt|Q1GgbI91e3CxdDDteZRifGmxbh?= M2i3ZlI2OTV{MkS1
SKOV-3 MWXBdI91d3OrczDBd5NigQ>? M{D2bVExKM7:TR?= M4Lqe|Q5KGh? M4jZO2ROW09? MWDJcoR2[2W|IHHwc5B1d3OrczDpckBUU0:YLUOgZ4VtdHNiaHHyZo92emmwZzDQTWs{S0FiaH;0d5BwfCCvdYTheIlwdg>? MlHLNlUyPTJ{NEW=
BSY-1 MXfBdI91d3OrczDBd5NigQ>? NGfhZZkyOCEQvF2= NHnzdmk1QCCq MkPDSG1UVw>? NHL6WWhKdmS3Y3XzJIFxd3C2b4Ppd{BqdiCEU2mtNUBk\WyuczDoZZJjd3W{aX7nJHBKUzOFQTDoc5R{eG:2IH31eIF1cW:w M4Hm[FI2OTV{MkS1
MKN-1 MVXBdI91d3OrczDBd5NigQ>? MkDCNVAh|ryP Mme1OFghcA>? M2\JZWROW09? NFjVUppKdmS3Y3XzJIFxd3C2b4Ppd{BqdiCPS16tNUBk\WyuczDoZZJjd3W{aX7nJHBKUzOFQTDoc5R{eG:2IH31eIF1cW:w MnvFNlUyPTJ{NEW=
NCI-H522 MXvBdI91d3OrczDBd5NigQ>? NXnZeVFxOTBizszN MlTPOFghcA>? NWnWV3JNTE2VTx?= M4nxcGlv\HWlZYOgZZBweHSxc3nz MWSyOVE2OjJ2NR?=
OVCAR-3 MV;BdI91d3OrczDBd5NigQ>? M1W0T|ExKM7:TR?= M4CwUVQ5KGh? MmPkSG1UVw>? NEjkcmNKdmS3Y3XzJIFxd3C2b4Ppdy=> M2f0d|I2OTV{MkS1
HBC-5 NHjKPY9CeG:2b4Ppd{BCe3OjeR?= M1eydlExKM7:TR?= M1LIZlQ5KGh? M3zse2ROW09? MW\JcoR2[2W|IHHwc5B1d3Orcx?= NYLrU2t4OjVzNUKyOFU>
RXF-631L MoTjRZBwfG:|aYOgRZN{[Xl? MoPMNVAh|ryP M4HRT|Q5KGh? NWG1WFJqTE2VTx?= NWnnXFVUUW6mdXPld{BieG:ydH;zbZM> M{LJdlI2OTV{MkS1
MKN-45 M2jpd2Fxd3Sxc3nzJGF{e2G7 MX2xNEDPxE1? Mn\pOFghcA>? M3XrV2ROW09? NF60NW1KdmS3Y3XzJIFxd3C2b4Ppdy=> MnG2NlUyPTJ{NEW=
BON-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2GwTFUxOCCwTR?= MonONVAh\A>? M2rtVGROW09? M4q4VGlvcGmkaYTzJINmdGxiZ4Lve5Rp M2fST|I2ODJ4Mkmy
BON-1 M4\IfWZ2dmO2aX;uJGF{e2G7 NUfoc4REPTByIH7N M1rYOFQhcA>? NV3nW3puTE2VTx?= NWHtd3NrUW6qaXLpeJMheGixc4Doc5J6dGG2aX;uJI9nKEGNVDDheEBVcHJ|MEigZY5lKFOnckS3Ny=> NFvYUpgzPTB{NkK5Ni=>
QGP-1 MYrGeY5kfGmxbjDBd5NigQ>? M{fCO|UxOCCwTR?= M4rMT|QhcA>? M{\RVGROW09? MYPJcohq[mm2czDwbI9{eGixconsZZRqd25ib3[gRWtVKGG2IGTodlMxQCCjbnSgV4VzPDd| MUmyOVAzPjJ7Mh?=
Huh7 MX7GeY5kfGmxbjDBd5NigQ>? MXKxJO69VQ>? Mln4NUBp NXzlPVVHTE2VTx?= MYjJcohq[mm2czDwbI9{eGixconsZZRqd25ib3[gRWtVKGG2IGPldlQ4PA>? Mn;MNlUxODR2MEO=
BNL M4\lZWZ2dmO2aX;uJGF{e2G7 NGK5[WQyKM7:TR?= Mor3NUBp NIDV[IJFVVOR NFfqZVdKdmirYnn0d{BxcG:|cHjvdplt[XSrb36gc4YhWzZ? MUSyOVAxPDRyMx?=
MDA-MB-175 NYPMXnVFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzoNUDPxE1? MkT4OUBl MVjEUXNQ NG\2THdKSzVyPEGg{txO NEfWUmUzPDh5OUe5Oi=>
MDA-MB-134 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;XUFBPOSEQvF2= MljiOUBl M3m0N2ROW09? MXvJR|UxRDFizszN NHWzO2QzPDh5OUe5Oi=>
HCC1500 Ml;ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\lNUDPxE1? MoTlOUBl M3raUGROW09? NFfSdGJKSzVyPEGg{txO M4jCeFI1QDd7N{m2
EFM-19 NXz4[4N3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUGxJO69VQ>? MlzlOUBl NHGz[3pFVVOR NHrkNmdKSzVyPEGg{txO M17HO|I1QDd7N{m2
ZR-75-30 M2PoN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPsNUDPxE1? M374WlUh\A>? MoDySG1UVw>? NFyy[HRKSzVyPEGg{txO NXrMbGNROjR6N{m3PVY>
MDA-MB-361 NIrDVIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVexJO69VQ>? NH7FeVg2KGR? MVLEUXNQ NYT0[ohmUUN3MEyxJO69VQ>? M{\h[FI1QDd7N{m2
T-47D MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVuxJO69VQ>? M2LpelUh\A>? MmDrSG1UVw>? M1nsOmlEPTB:MTFOwG0> NWfvWphXOjR6N{m3PVY>
SK-BR-3 NFjJc2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUD0fXdtOSEQvF2= MnP5OUBl MnvWSG1UVw>? NF3neI9KSzVyPEGg{txO NHewTY8zPDh5OUe5Oi=>
UACC-732 MnqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TT[VEh|ryP MnPiOUBl MoLDSG1UVw>? NXfrRXo{UUN3MEyxJO69VQ>? MYCyOFg4QTd7Nh?=
BT-474 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFu2SGIyKM7:TR?= NUHOcFRPPSCm NFz3RZdFVVOR MUXJR|UxRDFizszN NXW2VpNqOjR6N{m3PVY>
HCC202 NVrlSpROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPINUDPxE1? MWS1JIQ> NH;EbnhFVVOR M{H3UmlEPTB:MTFOwG0> MWCyOFg4QTd7Nh?=
MCF7 M4\h[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzYNUDPxE1? NX\6PJJpPSCm MULEUXNQ NIHLPWNKSzVyPEGg{txO M2jWelI1QDd7N{m2
MDA-MB-415 NYXzNG9UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX2xJO69VQ>? NFvFWoU2KGR? NVuxWnpvTE2VTx?= NHSxWnlKSzVyPEGg{txO NGn5O4ozPDh5OUe5Oi=>
MDA-MB-453 M3PzWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWKxJO69VQ>? NHLtRmY2KGR? M4GwTGROW09? M{KwRWlEPTB:MTFOwG0> NXnPb5lFOjR6N{m3PVY>
ZR-75-1 M1PZe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2Lv[VEh|ryP M4TrTVUh\A>? NFX5eXFFVVOR NXHzc2xNUUN3MEyxJO69VQ>? Mny1NlQ5Pzl5OU[=
HCC38 NXLHZ41ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7NUpZZOSEQvF2= NFfCWI82KGR? MmTzSG1UVw>? M1PMTWlEPTB:MTFOwG0> M{nleVI1QDd7N{m2
HCC1419 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4O5NlEh|ryP MWm1JIQ> MUPEUXNQ NInwTIlKSzVyPEGg{txO MnTWNlQ5Pzl5OU[=
UACC-812 NFjDSVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfrOZpCOSEQvF2= MlyxOUBl NHniWlFFVVOR NX;jSohmUUN3MEyxJO69VQ>? NGnaR5IzPDh5OUe5Oi=>
HCC1187 Ml7aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnvNGQyKM7:TR?= MoTLOUBl MXXEUXNQ NUTqfGRPUUN3MEyxJO69VQ>? MUOyOFg4QTd7Nh?=
KPL-1 Mnv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;QclEh|ryP M3LDNFUh\A>? MlfCSG1UVw>? M3r5cWlEPTB:MTFOwG0> NUK1emlPOjR6N{m3PVY>
SUM-225 Mny0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGX2[XIyKM7:TR?= MYm1JIQ> NEmwNoJFVVOR NHfmZoZKSzVyPEGg{txO NVvaUXFmOjR6N{m3PVY>
EFM-192A NYLlTIM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYCxJO69VQ>? MoLPOUBl NUP3cIg1TE2VTx?= NWnzOIh7UUN3MEyxJO69VQ>? NFXr[okzPDh5OUe5Oi=>
JIMT-1 MkX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{juWVEh|ryP MXK1JIQ> M1GxbWROW09? NYTHW|BqUUN3MEyxJO69VQ>? MknXNlQ5Pzl5OU[=
HCC1143 NHzXUm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUCxJO69VQ>? M3y1eVUh\A>? M1j0RmROW09? NGPROnVKSzVyPEGg{txO MmDINlQ5Pzl5OU[=
HCC2218 NYnsRWl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfMTIh7OSEQvF2= Mny3OUBl M3LhWmROW09? M2PYUGlEPTB:MTFOwG0> NIfQTYszPDh5OUe5Oi=>
MDA-MB-468 NIXkcmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV6xJO69VQ>? MWC1JIQ> Mo[3SG1UVw>? M2j2[mlEPTB:MTFOwG0> MY[yOFg4QTd7Nh?=
BT-20 NHj1XYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGe2W2syKM7:TR?= M3TmZVUh\A>? M4DEe2ROW09? NFXsS5ZKSzVyPEGg{txO NFzJfpkzPDh5OUe5Oi=>
MDA-MB-435 NYG2XoQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zqSVEh|ryP M2jvPFUh\A>? NInXbGVFVVOR NYf1NY9pUUN3MEyxJO69VQ>? NFT2OZIzPDh5OUe5Oi=>
BT-549 NGP4XXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\p[oNFOSEQvF2= MV[1JIQ> NWP5U5NrTE2VTx?= NXLlWItMUUN3MEyxJO69VQ>? MWCyOFg4QTd7Nh?=
HCC1806 MkjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\wT|AyKM7:TR?= Mly2OUBl NEGzN4NFVVOR M3;x[GlEPTB:MTFOwG0> MYWyOFg4QTd7Nh?=
HCC1937 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzwNUDPxE1? NUDPOo1zPSCm M2DJNGROW09? MmTETWM2ODxzIN88US=> NEPTUYozPDh5OUe5Oi=>
Hs578T NH\zXHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DseFEh|ryP NEPqTYs2KGR? MoHxSG1UVw>? NUDaTIFWUUN3MEyxJO69VQ>? Ml7hNlQ5Pzl5OU[=
LN18 MonNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfMNlAh|ryP NF\PZlg4OiCq MVfEUXNQ M3e3fWlEPTB:NTFOwG0> M3;ublI1PzRzMEe0
LN229 NYm0SJB5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUKyNEDPxE1? NHTr[pQ4OiCq MWXEUXNQ MWPJR|UxRDVizszN M{\xPVI1PzRzMEe0
LNZ308 MofSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MViyNEDPxE1? M3HzdFczKGh? Mk\XSG1UVw>? NVn6fotmUUN3MEy1JO69VQ>? MkPPNlQ4PDFyN{S=
T98G NHjoW4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17UcVIxKM7:TR?= MofiO|IhcA>? M4H1RmROW09? MknhTWM2ODx3IN88US=> MXiyOFc1OTB5NB?=
U87 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3eyPVIxKM7:TR?= MX63NkBp NInjNWlFVVOR NGD5OGRKSzVyPEWg{txO Mn;wNlQ4PDFyN{S=
LN18 MnvESpVv[3Srb36gRZN{[Xl? NFLpU482KM7:TR?= MUSyOEBp Mnm5SG1UVw>? MUjJcohq[mm2czDwbI9{eGixconsZZRqd25ib3[gRWtV MXGyOFc1OTB5NB?=
LNZ308 M4raPGZ2dmO2aX;uJGF{e2G7 NHjXNoE2KM7:TR?= NEP6XZozPCCq M2DCbmROW09? M3ewN2lvcGmkaYTzJJBpd3OyaH;yfYxifGmxbjDv[kBCU1R? NWLpeWVQOjR5NEGwO|Q>
Saos-2 NXHw[XlETnWwY4Tpc44hSXO|YYm= M3;nS|UxKM7:TR?= Ml\nOFghcA>? MVvJcohq[mm2czDj[YxtKGmwdnHzbY9v MkDVNlQ4Ojd4NkC=
MG-63 NV3RSIxsTnWwY4Tpc44hSXO|YYm= NUXvdmNqPTBizszN NV;BZW9WPDhiaB?= M4rFbmlvcGmkaYTzJINmdGxiaX72ZZNqd25? NEfUU5UzPDd{N{[2NC=>
SJSA-1 M1v5fGZ2dmO2aX;uJGF{e2G7 NHHUdZI2OCEQvF2= M2rZOVQ5KGh? NX7mfY9nUW6qaXLpeJMh[2WubDDpcpZie2mxbh?= NXTZ[I1wOjR5Mke2OlA>
Saos-2 Mk[0SpVv[3Srb36gRZN{[Xl? MmHaOVAh|ryP NWPab25xPDhiaB?= MXXJcohq[mm2czDtZZRzcXhibXX0ZYxtd3C{b4TlbY5ie2VvMjDlfJBz\XO|aX;u M3TjcVI1PzJ5Nk[w
MG-63 MoHlSpVv[3Srb36gRZN{[Xl? MkHyOVAh|ryP M37qWFQ5KGh? NETFR|dKdmirYnn0d{Bu[XS{aYigcYV1[Wyub4Dyc5RmcW6jc3WtNkBmgHC{ZYPzbY9v M4rVUlI1PzJ5Nk[w
SJSA-1 MkDhSpVv[3Srb36gRZN{[Xl? MoPIOVAh|ryP MmTJOFghcA>? NX;4bXg2UW6qaXLpeJMhdWG2cnn4JI1mfGGubH;wdo91\WmwYYPlMVIh\XiycnXzd4lwdg>? MViyOFczPzZ4MB?=
Saos-2 M1PUTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXYOVAh|ryP MofDOFghcA>? MY\Jcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? NV;FOoVMOjR5Mke2OlA>
MG-63 M2PzOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDxfnA2OCEQvF2= NHfKV4Y1QCCq NV\FfWhbUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= MVmyOFczPzZ4MB?=
SJSA-1 NXO5TJVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXIUHFpPTBizszN NH3leZc1QCCq MnLaTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? NEfieGgzPDd{N{[2NC=>
FaDu MmL2SpVv[3Srb36gRZN{[Xl? M3PZPFUh|ryP NGjuXpIzPCCq MWTEUXNQ MkjYVoVlfWOnczDvfJlo\W5iY3;ud5VueHSrb36= M3HvRVI1PjNzMUS3
EMT6 NHvmelVHfW6ldHnvckBCe3OjeR?= M17ENlUh|ryP NXrsb2s3OjRiaB?= MorxSG1UVw>? M2P4N3Jm\HWlZYOgc5h6\2WwIHPvcpN2dXC2aX;u NH;kdW8zPDZ|MUG0Oy=>
HCT116 MXPGeY5kfGmxbjDBd5NigQ>? NUHWUI0{PSEQvF2= MmPyNlQhcA>? MXLEUXNQ NIjyRlRT\WS3Y3XzJI95gWenbjDjc45{fW2ydHnvci=> MVWyOFY{OTF2Nx?=
U87 MY\GeY5kfGmxbjDBd5NigQ>? NYDaPXlFPSEQvF2= NHnvdpQzPCCq NXz2W5JlTE2VTx?= NEC0Rm1T\WS3Y3XzJI95gWenbjDjc45{fW2ydHnvci=> MljzNlQ3OzFzNEe=
GBM MmXBRZBweHSxc3nzJGF{e2G7 M1nEfFLPxE1? MY[0PIg> M4r0dmROW09? NHrvd2ZqdmS3Y3XkJIhq\2incjDs[ZZmdHNib3[gZZBweHSxc3nzMEBidmRiZHXjdoVie2WmIHPlcIwhfmmjYnnsbZR6 NWrhXZBSOjR3MEC0PVI>
BON NWnCc4EzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvmNU02|ryP MofpO|Jp NWX6XFZy\GWlcnXhd4V{KGOnbHygdJJwdGmoZYLheIlwdg>? M1LLbVI1PDR|NUKz
BON NEjGV49CeG:ydH;zbZMhSXO|YYm= NX\0W4tFOS13zszN M4ruS|I1cA>? M2DoWolv[3KnYYPld{BieG:ydH;zbZM> NGjWb3EzPDR2M{WyNy=>
H1975 NI\DfIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1L5fFAvOy17LkdOwG0> MmTzO|Jp MVHEUXNQ MlX2TWM2OD1zLkO4Oe69VQ>? MnqyNlQ{Ozd6NE[=
H1975 MnH0RZBweHSxc3nzJGF{e2G7 MWiy{txO NEfVSVEzPGh? M{\EVWROW09? MnXPbY5kemWjc3XzJIFxd3C2b4Ppd{Bz[XSnIIPp[45q\mmlYX70cJk> MnTyNlQ{Ozd6NE[=
T-ALL NInKWldCeG:ydH;zbZMhSXO|YYm= NGm3TXNj\XS5ZXXuJFEvPCCjbnSgOU4{KG2PIHH0JFI1cCCjbnSgNE46KGGwZDC1MlUhdU1iYYSgOFhpKGmwIHTp[oZmemWwdDDj[YxtKGyrbnW= M2j3d|I1KG:{IES4bC=> MYLEUXNQ NH;CWGdi\m[nY4TzJJRp\SCSSUPLJJBifGi5YYmgbY4hXC2DTFygZ4VtdCCuaX7ldy=> M3HKOVI1OzFyN{O2
BCR-ABL MmTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHywUlYxNjJ3LUGw{txO M3;pPVRl NULWUY4ye2mpbnnmbYNidnSueTDpcohq[mm2IHPlcIwheHKxbHnm[ZJifGmxbh?= M4D3R|I1OjR2NkGy
LC-1/SQSF M4OxR2Z2dmO2aX;uJGF{e2G7 NEnFUYY{|ryP NGrTfGwzPGh? M{\Y[GROW09? M{nJS4Rm[3KnYYPlJG5TTjJicILveIVqdiCuZY\lcC=> MkDsNlM6QDByOUO=
Primary CLL cells NYHROYd7SXCxcITvd4l{KEG|c3H5 NUTINnpTOS1zMN88US=> NVTVTnN3PDiq MUfpcoR2[2W|IHHwc5B1d3OrczDpckBEVExiY3XscJMhcW6mZYDlcoRmdnRib3[gdJJw\26xc4TpZ{Bu[XKtZYLz M1vqSFI{QDVyOEC3
Primary CLL cells MmHJT4lv[XOnIFHzd4F6 MmPTNu69VQ>? NGXS[2c{OG2rbh?= NUPQe5c4\GWlcnXhd4VlKFCLM1ugZYN1cX[rdIm= MWqyN|g2ODhyNx?=
Primary CLL cells MVPDfZRwfG:6aXOgRZN{[Xl? NVvEXodxOs7:TR?= MVeyOIg> NIPqUVlqdmS3Y3XzJINmdGxiY4n0c5RwgGmlaYT5 MVWyN|g2ODhyNx?=
human NSCLC cell lines M4nWOmFxd3C2b4Ppd{BCe3OjeR?= Mlu1NE4yOjVvNN88US=> M4XM[FI1cA>? MlrNSG1UVw>? NIX4S41KSzVyczDyZY5o\XNiZoLvcUAxNjRvMt88US=> MWqyN|U3OjR5Mh?=
human HCC cell lines NHrt[GFE\WyuII\pZYJqdGm2eTDhd5NigQ>? NXrvW4w6OC5yMEWtNe69VQ>? NILhXYw1QGh? MXTJR|UxRTIQvF2= NGfZepgzOzR6OUm5PS=>
Huh7 M1;6NGtqdmG|ZTDBd5NigQ>? NE\SO2sy|ryP MXy0PIg> NYqyfVJSe2mpbnpvsKFk[W62bImgdoVlfWOnczDwbI9{eGixconsZZRqd25ib3[gRYt1 MUKyN|Q5QTl7OR?=
SK-HEP1 NXvsWJI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvpdppDOS1{MN88US=> NYDuem9TPzKq NXi3[opJTE2VTx?= M{\GcmlEPTExvKyx{txO Mn7FNlM1PzlzM{[=
786-0 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jVZ|EuOjEQvF2= MnL4O|Jp MYLEUXNQ MV3JR|Ux97zeMd88US=> M36ydlI{PDd7MUO2
JVM2 MlPZR5l1d3SxeHnjbZR6KGG|c3H5 M{LKUVAvOi1{MN88US=> MXK3Nog> M4DxPGROW09? MojoTWM2OD1yLkpOwG0> NGPFSYgzOzJ|OE[zPS=>
EHEB MlfMR5l1d3SxeHnjbZR6KGG|c3H5 MUSwMlIuOjEQvF2= NYLqbYlnPzKq NXrpUJhPTE2VTx?= MmTkTWM2OD1yLkhOwG0> MkHwNlMzOzh4M{m=
MEC2 NEnsVo5EgXSxdH;4bYNqfHliYYPzZZk> NFT5Z4wxNjJvMkFOwG0> MnnkO|Jp MYnEUXNQ M4PZU2lEPTB;MD63{txO NYDQenNnOjN{M{i2N|k>
primary B-CLL lymphocytes M2\JVGFxd3C2b4Ppd{BCe3OjeR?= NHHwXVRKSzVyIH\vdkBm[WOqIIDybY1ienliY3XscEBtcW6n M2D1e|I1cA>? M{PLfWROW09? NFnGTXBKSzVy78{cN:69VSCob4KgZYxtKHCjdHnlcpR{ Mny1NlMzOzh4M{m=
primary B-CLL lymphocytes MYLLbY5ie2ViQYPzZZk> NIexeXpKSzVyIH\vdkBm[WOqIIDybY1ienliY3XscEBtcW6n MlnYNlRp MkD5bY5pcWKrdIOgdFcxWz[NID[gOGUuSlBzIHX4dJJme3Orb36= NFLpNFEzOzJ|OE[zPS=>
human NSCLC NWjte2FCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF[0cVYxNjVvMt88US=> M3rBS|czcA>? MVjJR|UxRTIQvF2= NU\WcpF5OjJ5OEGzPVM>
human NSCLC NX7WbppNU2mwYYPlJGF{e2G7 NYC4WZNzOc7:TR?= NWPDcpJDOjSq M2nuOolvcGmkaYTzJJRp\SCDa4SvcXRQWiC|aXfuZYxqdmdicHH0bJdigSCjdDCzbEBi\nSncjD0doVifG2nboS= MViyNlc5OTN7Mx?=
Y1 cell line M3rlXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV:0fHhKOC5zzszNM|HPxE1? MUWyOIg> NYPibJdwTE2VTx?= Mn7rbY5pcWKrdIOgOlDwxIViY3XscEB3cWGkaXzpeJkhcW5iTYnjMXNkfHJvdILhcpNn\WO2ZXSgZ4VtdHN? M4fkTVIzPjl{OUC0
PIK3CA-mutant MCF7 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHHTVUxRTF4MNMxPVFvVe,:jFzEOVA:QThywsGyO|NvVQ>? MlfiO|Jp NW\QVoY{T0l3ME2xOlDDuTlzbl5vwKxNTDVyPUm4NOKyOjd|bl2= NV3teIN6OjJ4NUO5Olc>
PIK3CA-mutant MCF7 NFm3[GFMcW6jc3WgRZN{[Xl? MVrJR|UxRTFzNNMxN45O NXuwVZFPPzKq NWnSTpBFUUN3ME2xNVTDuTOwTTDpckBz\WS3Y3nu[{BCc3RicHjvd5Bpd3K7bHH0bY9vKGyndnXsdy=> MY[yNlY2Ozl4Nx?=
MCF7-myr-Akt MoTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTjdJJ2T0l3ME2yPVnDuTZ6bl5vwKxNTDVy78{eNVAtODBybl2= M1yzVFczcA>? NWrDeFM1T0l3ME2yPVnDuTZ6bl5vwKxNTDVy78{eNVAtODBybl2= NYnSSG1bOjJ4NUO5Olc>
colon cancer cell lines NWPZfJdsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1KwO|AuOTEQvF2= NHXp[HU4Omh? NIjGVmtFVVOR NUPwfI1zUUN3ME2x{txO NIft[IEzOjV2M{i1Oy=>
gastric cancer cell lines MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2P1PFAuOTEQvF2= MlPXO|Jp NX[3No5FTE2VTx?= MkP2TWM2OD1{LUZOwG0> NVnaNFEyOjJ3NEO4OVc>
HCT-116/HT-29/MKN-45 NXfs[GM{SXCxcITvd4l{KEG|c3H5 MlTLNu69VQ>? M{LEV|Q5cA>? NUPEVGVue2irZoSgbY4hTzJicHjhd4U> NWPaN|JCOjJ3NEO4OVc>
HT-29 and HCT-116 M2PrT2Nie3Cjc3WgZZN{[Xl? MWW1{txO NX7Sc29KOjSq NWDBUYJVcW6mdXPld{Bk[XOyYYPlJIFkfGm4aYT5 M17tN|IzPTR|OEW3
MM cell lines NHPTPZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrjNVDPxE1? M4n1elI1cA>? NEnmc41FVVOR M{TNfWlEPTBidnHybYV{KGGvb37nJIRq\m[ncnXueEBk\WyuIHzpcoV{KGmwIITpcYUh[W6mIHTvd4Uh\GWyZX7k[Y5k\Q>? M3TvR|IzOjB5NEi1
ARP-1 MnPiRZBweHSxc3nzJGF{e2G7 NF3rVVIyOM7:TR?= M4LNZ|I1cA>? M2LBR2ROW09? NYTTWYM5cW6mdXPld{BOVSClZXzsJIFxd3C2b4Ppd{B1cHKxdXfoJINie3Cjc3WgZYN1cX[jdHnvci=> MVqyNlIxPzR6NR?=
SNU-601 NUnYRXNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPLRpNqPzKq NYDLWmdTTE2VTx?= NXS5[HhKUUN3ME2wMlgyPsLzMD6wOlPPxE1? M1f4clIzOTV7OEG0
SNU-1 MorqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDhZm44Omh? MWnEUXNQ MV7JR|UxRTFwMEiyxtExNjB{ON88US=> M{DheFIzOTV7OEG0
SNU-668 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XWd|czcA>? MmXVSG1UVw>? NV3kOpNYUUN3ME2xMlU4QcLzMD6wO|TPxE1? NYmz[XdDOjJzNUm4NVQ>
AGS NWfBZ2RET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLiO|Jp NEm5NIRFVVOR NHvveFVKSzVyPUGuO|E1yrFyLkGxO:69VQ>? NHLINmQzOjF3OUixOC=>
SNU-216 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXuxNGE6PzKq NHzjWVBFVVOR NFrKUINKSzVyPUKuOlkzyrFyLkC4Nu69VQ>? Mn\2NlIyPTl6MUS=
SNU-5 M3S0T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfKO|Jp NVLmNYV7TE2VTx?= MXnJR|UxRTFwM{WxxtExNjB7Md88US=> NYT0U4Y5OjJzNUm4NVQ>
SNU-638 Ml;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HoS|czcA>? MVXEUXNQ M3HG[GlEPTB;Mj6yPFLDuTBwMEWz{txO NV\sdItCOjJzNUm4NVQ>
SNU-16 M2mx[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvSfVA4Omh? MnXkSG1UVw>? NUGxb41VUUN3ME2xMlU4O8LzMD6wNFHPxE1? M3LSRVIzOTV7OEG0
SNU-484 NGr0[ZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX63Nog> NG\PXGFFVVOR MWPJR|UxRTFwN{K4xtExNjB2Nd88US=> MWCyNlE2QThzNB?=
SNU-620 M1zOd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYC3Nog> M1jGcmROW09? MVjJR|UxRTJwOUO5xtExNjByMd88US=> MojhNlIyPTl6MUS=
SNU-719 MkCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPqcVVFPzKq M3z5UmROW09? NXzxPFVzUUN3ME2zMlA{P8LzMD6wN|LPxE1? NEW4dlkzOjF3OUixOC=>
glioma cell lines MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M176SFczcA>? MnzCTWM2OD1zLUNOwG0> NH24dWQzOjB4NUC4NC=>
U87 M2HUbWFxd3C2b4Ppd{BCe3OjeR?= MmX2Nu69VQ>? M{WxZlczcA>? NHO2do5qdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHHu[EBkdGWjdnXkJHBCWlBiYX7kJINie3Cjc3WtNy=> NFH3XZAzOjB4NUC4NC=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-AKT (T308) / p-AKT (S473) / AKT; 

PubMed: 27283525     


Left western blots showing levels of pAkt (T308), pAkt (S473) and total Akt in U87 cells exposed to buparlisib for 72 h. Right densitometric assessment of western blots, showing relative changes in phosphorylation.

p-FOXO3a (S253) / FOXO3a; 

PubMed: 28036259     


Cells were treated with 0.5 μM BKM120 for 24 h and cell lysates were immunoblotted with the indicated antibodies. Actin was used as the loading control.

Nuclear NF-κB p65 / NF-κB p65; 

PubMed: 26673665     


Western blots show BKM120 downregulating pAKT, nuclear NF-κB p65 and total NF-κB p65 in MDR and their parental cells. β-actin was used as a loading control for pAKT, AKT and total NF-κB p65. Lamin B was used as a loading control for nuclear NF-κB p65. 

p-ERK / ERK / LC3; 

PubMed: 27572309     


The indicated cell lines were exposed to different concentrations of BKM120 as indicated for 8 h A. or with 2 μM BKM120 for the indicated times B. The cells were then harvested for preparation of whole-cell protein lysates and subsequent Western blot analysis to detect the given proteins.

p-STAT3 / STAT3 / p-ERK / ERK / p-S6; 

PubMed: 29928341     


Western blot analysis of H460 and H2126 cell lysates using specific antibodies to phosphorylated or total proteins of STAT3, ERK1/2, AKT, S6 or GAPDH (loading control). The cells were treated with increasing concentrations of BKM120 for 24 h.

p-MET / MET; 

PubMed: 29928341     


The expression of phosphorylated or total forms of MET protein was analyzed by western blotting. 

27283525 28036259 26673665 27572309 29928341
Immunofluorescence
FOXO3a; 

PubMed: 28036259     


Cells were cultured on coverslips to approximately 60% confluency and then treated with 1 μM BKM120 for an additional 24 h. Immunofluorescence staining was performed using an anti-FOXO3a antibody and the nuclei were stained with DAPI. Scale bar, 20 μm.

28036259
Growth inhibition assay
Cell viability; 

PubMed: 26673665     


Dose-response curves were used to calculate the IC50 of BKM120 for MCs of MCF-7/A02 cells (upper) and CALDOX cells (lower).

26673665
In vivo BKM120 completely inhibits pAktser473 in A2780 xenograft tumors at doses of 30, 60, or 100 mg/kg, respectively. BKM120 also shows antitumor activity against U87MG glioma model at doses of 30 and 60 mg/kg. [1] BKM120 treatment results in significantly reduced tumor volume and level of circulating human kappa chain at 5 μM/kg/day−1in ARP1 SCID mouse model, with prolonged survival. [2]

Protocol

Kinase Assay:[1]
+ Expand

PI3K biochemical assay (ATP depletion assay):

BKM120 is dissolved in DMSO and directly distributed into a black 384-well plate at 1.25 µL per well. To start the reaction, 25 µL of 10 nM PI3 kinase and 5 µg/mL 1-α-phosphatidylinositol (PI) in assay buffer (10 mM Tris pH 7.5, 5 mM MgCl2, 20 mM NaCl, 1 mM DTT and 0.05% CHAPS) are added into each well followed by 25 µL of 2 µM ATP in assay buffer. The reaction is performed until approx 50% of the ATP is depleted and then stopped by the addition of 25 µL of KinaseGlo solution. The stopped reaction is incubated for 5 minutes and the remaining ATP is then detected via luminescence.
Cell Research:[1]
+ Expand
  • Cell lines: A2780 cells.
  • Concentrations: 0-6.6 μM
  • Incubation Time: 3 days.
  • Method: A2780 cells are cultured in DMEM supplemented with 10% FBS, L-glutamine, sodium pyruvate, and antibiotics. Cells are plated in the same medium at a density of 103 cells per well, 100 μL per well into black-walled-clear-bottom plates and incubated for 3-5 hours. BKM120 supplied in DMSO (20 mM) is diluted. The diluted BKM120 solution (2 μL), is then added to cell medium (500 μL) cell medium (concentration from 0-6.6 μM). Equal volumes of this solution (100 μL) are added to the cells in 96 well plates and incubated at 37 °C for 3 days and developed using Cell Titer Glo. Inhibition of cell proliferation is determined by luminescence read using Trilux.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: U87MG and A2780 xenografts are established in female nu/nu mice.
  • Formulation: In 15% Captisol.
  • Dosages: ~60 mg/kg.
  • Administration: Dosed orally daily (q.d.).
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 82 mg/mL (199.8 mM)
Ethanol 2 mg/mL (4.87 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 410.39
Formula

C18H21F3N6O2

CAS No. 944396-07-0
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02756247 Active not recruiting Lymphoma|Mantle Cell Lymphoma|Follicular Lymphoma|Diffuse Large B Cell Lymphoma Memorial Sloan Kettering Cancer Center|Janssen Scientific Affairs LLC|Novartis Pharmaceuticals May 2016 Phase 1
NCT02756247 Active not recruiting Lymphoma|Mantle Cell Lymphoma|Follicular Lymphoma|Diffuse Large B Cell Lymphoma Memorial Sloan Kettering Cancer Center|Janssen Scientific Affairs LLC|Novartis Pharmaceuticals May 2016 Phase 1
NCT02614508 Active not recruiting Recurrent Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma Emory University|Novartis January 2016 Phase 1
NCT02614508 Active not recruiting Recurrent Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma Emory University|Novartis January 2016 Phase 1
NCT01613677 Withdrawn Treatment for Metastatic or Locally Advanced Cervical Cancer Novartis Pharmaceuticals|Novartis November 2015 Phase 2
NCT01613677 Withdrawn Treatment for Metastatic or Locally Advanced Cervical Cancer Novartis Pharmaceuticals|Novartis November 2015 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products5

Tags: buy Buparlisib (BKM120, NVP-BKM120) | Buparlisib (BKM120, NVP-BKM120) supplier | purchase Buparlisib (BKM120, NVP-BKM120) | Buparlisib (BKM120, NVP-BKM120) cost | Buparlisib (BKM120, NVP-BKM120) manufacturer | order Buparlisib (BKM120, NVP-BKM120) | Buparlisib (BKM120, NVP-BKM120) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID